Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | TDO2 | P48775 | 1/20 | 0.58 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.58 |
| ▸ | HPD | P32754 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602737 | 0.88 | L3MBTL1 (0.74) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6601051 | 0.87 | ALDH1A1 (0.70) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6214003 | 0.87 | TDO2 (0.57) | TDO2IDO2 | |
| SCHEMBL6601150 | 0.85 | L3MBTL1 (0.62) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6220136 | 0.84 | L3MBTL1 (0.55) | L3MBTL1GLATDO2IDO2 | |
| Mecloqualone SCHEMBL113419 | 0.84 | ALDH1A1 (0.73) | L3MBTL1GLATDO2IDO2HPD | |
| Mecloqualone SCHEMBL29437131 | 0.84 | ALDH1A1 (0.73) | L3MBTL1GLATDO2IDO2HPD | |
| Mecloqualone SCHEMBL30726100 | 0.84 | ALDH1A1 (0.73) | L3MBTL1GLATDO2IDO2HPD | |
| Mecloqualone SCHEMBL30726104 | 0.84 | ALDH1A1 (0.73) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6216766 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884310-B1 | Quinazolin-4-one ampa antagonists | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6921764-B2 | Thieno-pyrimidin-4-one AMPA antagonists | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-0901487-B9 | 2,3,6 TRISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-0968194-B1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-0964860-B1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PROD INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6627755-B1 | Neurodegenerative, psychological, and nervous system disorder; drug abuse, alcoholism | PFIZER INC | 2003-09-30 | — | — | US | disclosed |
| EP-0901487-B1 | 2,3,6 TRISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| CN-1420114-A | 2,3-disubstd. -4(3H)-quinazolones | PFIZER (US) | 2003-05-28 | — | — | CN | disclosed |
| CN-1103772-C | Novel 2, 3-disubstituted-4 (3H) -quinazolinones | PFIZER (US) | 2003-03-26 | — | — | CN | disclosed |
| EP-0964860-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0934934-A2 | Methods of preparing substituted 3-phenyl- and 3-pyridyl-4(3H)-quinazolinones and atropisomers thereof | Pfizer Products Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| CN-1218464-A | Novel 2, 3-disubstituted-4 (3H) -quinazolinones | PFIZER (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0901487-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0900567-A2 | Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0884310-A1 | Quinazolin-4-one ampa antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0884316-A1 | Quinazoline-4-one AMPA antagonists | Pfizer Products Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1998038173-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998038187-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997043276-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049039-A1 | Quinazolin-4-one ampa antagonists | GRIN1, GRIK1, GRIN3A | L3MBTL1 3272/4885GLA 4558/4885TDO2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.